AZ
Therapeutic Areas
Molecular Partners Pipeline
| Drug | Indication | Phase |
|---|---|---|
| MP0533 | Acute Myeloid Leukemia (AML) | Phase 1/2a |
| MP0317 | Solid Tumors | Phase 1 |
| MP0712 | Small Cell Lung Cancer & Neuroendocrine Cancers | Preclinical |
| Switch-DARPin Platform | Various Oncology Targets | Discovery/Preclinical |
| Radio-DARPin Platform | Various Oncology Targets | Discovery/Preclinical |
Leadership Team at Molecular Partners
PA
Patrick Amstutz, Ph.D.
Chief Executive Officer
PL
Philippe Legenne, M.D.
Chief Medical Officer
MS
Martin Steegmaier, Ph.D.
Chief Scientific Officer
MT
Michael Tobias Stumpp, Ph.D.
EVP Projects
RG
Renate Gloggner
EVP People and Community
MP
Michael Pitzner
EVP General Counsel and Partnering
SL
Seth Lewis
EVP Corporate Finance
RH
Robert Hendriks
SVP Finance
DS
Daniel Steiner, Ph.D.
SVP Research & Technology
LJ
Laura Jeanbart, Ph.D.
Head of Portfolio Management and Corporate Communications